| Description | D-3263 is an agonist of transient receptor potential melatonin member 8 (TRPM8) with potential antitumor activity. |
| In vitro | D-3263 induces calcium flux and cell death in cells expressing TRPM8 in vitro. |
| In vivo | D-3263 alone (50 or 100 mg / kg / d) or in combination with finasteride (10 mg / kg / d) can lead to decreased prostate hyperplasia in rats, with evidence of dose response. The highest dose of TRPM8 agonist D-3263 combined with finasteride caused lower prostate weight than the highest dose of D-3263 or finasteride alone, indicating a potential additive effect. |
| molecular weight | 373.49 |
| Molecular formula | C21H31N3O3 |
| CAS | 947257-66-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. David Duncan, et al. PRECLINICAL EVALUATION OF THE TRPM8 ION CHANNEL AGONIST D-3263 FOR BENIGN PROSTATIC HYPERPLASIA. THE JOURNAL OF UROLOGY, Vol. 181, No. 4, Supplement, Tuesday, April 28, 2009 |